SAS Output

20-AUG-2018 6:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 457 222
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 267 131
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 460 209
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 272 122
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 471 244
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 230
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 64
  B51 Breast, Regional Nodal XRT 22-AUG-13 416 222
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 449 187
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 148 51
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 297 164
  EA1151 Brst, Tomosynthesis Mammographic Screening 06-JUL-17 0 68
  NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA 24-DEC-14 0 137
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 438 208
  NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 13-APR-17 0 6
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 25 33
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 189 51
  S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 0 23
  A011104 Preoperative Breast MRI 21-FEB-14 150 54
  A191402C PROS, Testing Decision Aids for Minority Men 14-JUL-17 0 10
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 355 164
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 393 180
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 294 110
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 263 120
  EAY131 MATCH 12-AUG-15 477 241
 
GI S1613 mCRC, Adv/Met, TP vs CETIRI 09-OCT-17 0 127
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 84
  A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC 12-SEP-17 0 34
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 183 74
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 161
  NRGGI002 Rectal, Ph II, Sensitization using TNT 12-OCT-16 331 141
  NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy 07-NOV-17 0 28
 
GU S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 225 95
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 151 63
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 166 72
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 66 35
  A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 21-SEP-17 0 104
  EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) 02-FEB-17 0 141
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 128
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 175
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 3 3
  S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics 22-DEC-17 0 73
  S1712 CML, chronic phase, TKI +/- Ruxolitinib 20-JUL-18 0 13
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 167 83
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 141 71
  NHLBIMDS LEUK, National MDS Study 05-APR-16 248 104
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 460 225
  S1400F Non-Match: MEDI4736 + Tremelimumab 02-OCT-17 0 229
  S1400K c-Met: ABBV-399 (Process II) 05-FEB-18 0 220
  S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 03-NOV-17 0 21
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 253
  A151216 ALCHEMIST0 - screening 06-FEB-14 477 250
  C30610 SCLC, Thoracic RT 21-MAR-08 208 109
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 472 252
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 447 242
  EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo 02-MAY-18 0 35
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 318 140
 
LYMPH S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob 10-AUG-17 0 105
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 164 72
  EA4151 Lymph, AHCT +/-Ritux, MRD Neg 29-AUG-17 0 17
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 226 100
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 89 42
  S1607 MELAN, Adv, T-VEC, MK-3475 02-OCT-17 0 19
  S1616 MELAN, Adv, Ipilimumab Nivolumab 17-JUL-17 0 94
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 364 156
  EA6141 Melan, Avd, Nivolumab+Ipi Sargmostim 01-MAR-16 306 121
 
MMYEL S1702 AL Amyloidosis, Relapsed, Isatuximab 08-MAR-18 0 49
  E1A11 MM, frontline, BLD vs CLD 22-NOV-13 336 144
 
OTHER A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 223 78
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 115 35
  A091401 Sarc, 18-JUN-15 237 90
  A091404 HN, AR+, Enzalutamide 25-SEP-15 80 41
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 74
  EAF151 Brain, GBM, Bev, Blood Volume 14-APR-17 0 30
  EAQ152 Communication & education in tumor profiling 26-SEP-16 253 108
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 76
  N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC 22-SEP-09 170 87
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 97
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 326 137
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 201 74
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 225 92
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 250 104
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 263 88
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 21 7
 
SURV S1316 Compar. Effectiv. Trial for MBO 01-AUG-14 7 11
  S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 96
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 44
  EA9131 Leuk, Strategy to decrease early APL deaths 16-AUG-17 0 24
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 89 41
  NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT 28-JUL-17 0 118